1,3-dimethyl-8-(4-methoxyphenyl)-9(H)-xanthine | 967-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,3-dimethyl-8-(4-methoxyphenyl)-9(H)-xanthine
• 英文别名: 8-<4-Methoxy-phenyl>-theophyllin；8-(4-methoxy-phenyl)-1,3-dimethyl-3,7(9)-dihydro-purine-2,6-dione；8-(4-Methoxy-phenyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione；8-(4-methoxyphenyl)-1,3-dimethyl-7H-purine-2,6-dione
• CAS: 967-42-0
• 化学式: C₁₄H₁₄N₄O₃
• 分子量: 286.29
• InChiKey: VPHSVCWZXWNVFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  78.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5,6-二氨基-1,3-二甲基脲嘧啶 在 吡啶 、 三氯化铝 、 phosphorus pentoxide 作用下， 以 吡啶 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 1,3-dimethyl-8-(4-methoxyphenyl)-9(H)-xanthine
  参考文献：
  名称：

  Synthesis and in vitro bronchospasmolytic activity of 8-aryl, heteroaryl or arylalkyl theophyllines

  摘要：

  Twenty-four 8-aryl- or 8-heteroaryl-substituted theophyllines have been synthesized. The substituents are aromatic rings and heterocycles likely to induce an antiallergic effect or a spasmolytic activity. In vitro evaluation of the bronchospasm caused by acetylcholine or histamine shows an interesting activity for half of the compounds. Among them, the furanic IIIs and 2-chlorophenyl IIIi derivatives are, for instance, four times more active than theophylline.

  DOI：

  10.1016/0223-5234(96)88233-x

文献信息

• Studies on heterocyclic compounds. XXXII. Synthesis of 8-substituted theophyllines from 6-amino-5-benzylideneamino-1,3-dimethyluracils with nickel peroxide.
  作者：SATOSHI MINEO、HARUO OGURA、KUNIO NAKAGAWA

  DOI：10.1248/cpb.28.2835

  日期：——

  Oxidation of 6-amino-5-benzylideneamino-1, 3-dimethyluracils (Ia-e) with nickel peroxide (Ni-PO) in dimethylsulfoxide (DMSO) afforded 8-substituted theophyllines (IIa-e) and dimethylsulfone. Ni-PO oxidation of the Schiff base acetate (V) of 5, 6-diamino-1, 3-dimethyluracil with D-glucose did not give a nucleoside analog ; in stead, 1, 3, 7, 9-tetramethyl-2, 4, 6, 8-(1H, 3H, 7H, 9H)pyrimido[5, 4-g]pteridinetetrone (VI) and penta-O-acetylgluconic acid were obtained. The reaction mechanisms of Ni-PO and the Schiff bases (Ia-e, V) are discussed.

  在二甲基亚砜（DMSO）中，6-氨基-5-苄叉氨基-1,3-二甲基脲（Ia-e）与过氧化镍（Ni-PO）的氧化反应生成了8-取代的茶碱（IIa-e）和二甲基亚砜。5,6-二氨基-1,3-二甲基脲与D-葡萄糖形成的希夫碱乙酸盐（V）在Ni-PO氧化下并未形成核苷类似物；取而代之，得到了1,3,7,9-四甲基-2,4,6,8-（1H,3H,7H,9H）嘧啶[5,4-g]蝶啶四酮（VI）和五-O-乙酰基葡糖酸。本文还讨论了Ni-PO与希夫碱（Ia-e, V）的反应机理。
• Pyrimidine derivatives and related compounds. Part 47. A new synthesis of xanthines and pyrrolo[3,2-d]pyrimidines by intramolecular cyclisation of 6-substituted 5-nitrouracil derivatives
  作者：Kosaku Hirota、Tadashi Sugiyama、Yukio Kitade、Shigeo Senda、Yoshifumi Maki

  DOI：10.1039/p19840000583

  日期：——

  of 6-[2-(ethoxycarbonyl, acetyl, and cyano) ethyl] uracil (8h–j) with triethylamine led to the formation of the corresponding 6-vinyluracil (11 a–c). A one-step synthesis of the 7-hydroxy-9-deazaxanthines (9a–e) was accomplished by the treatment of the sodium salt (7) with arylalkyl chlorides in the presence of potassium carbonate in dry DMF. Deoxygenation of the 7-hydroxy-9-deazaxanthines (9a–e) smoothly

  通过在三乙胺存在下使6-氯-1,3-二甲基-5-硝基尿嘧啶（1）与芳基烷基胺反应，制得6-芳烷基氨基-1,3-二甲基-5-硝基尿嘧啶（2a–f）。其中，在氮原子和6-芳基烷基氨基部分中的苄基位置不具有取代基的6-芳基烷基氨基尿嘧啶（2a–d）在转化为相应的8-芳基-1,3-二甲基黄嘌呤（3a–d）时在二甲基甲酰胺（DMF）中加热回流。钠盐（反应7 1,3,6-三甲基-5- nitrouracil（的）6）用在无水DMF烷基和芳基烷基卤化物，得到相应的6-（取代甲基）-1,3-二甲基-5-硝基尿嘧啶（8a–j）。其中，对6-（2-芳基乙基）尿嘧啶（8b-f）进行碱催化的环化反应，得到8-芳基-7-羟基-9-脱氮黄嘌呤（9a-e）。另一方面，用三乙胺处理6- [2-（乙氧羰基，乙酰基和氰基）乙基]尿嘧啶（8h-j）导致形成相应的6-乙烯基尿嘧啶（11a-c）。在干燥的DMF中，在碳酸钾的存在下
• Synthesis, DNA Binding and Antiviral Activity of New Uracil, Xanthine, and Pteridine Derivatives
  作者：Osama I. El-Sabbagh、Mohamed E. El-Sadek、Samar El-Kalyoubi、Ibrahim Ismail

  DOI：10.1002/ardp.200600149

  日期：2007.1

  Some new 6‐amino‐1,3‐dimethyl‐5‐(substituted methylidene)aminouracils were synthesized. Most of them were cyclized with triethyl orthoformate as a one‐carbon source to afford 1,3‐dimethyl‐6‐substituted pteridine derivatives. Certain uracils gave xanthine instead of the expected pteridine derivatives upon using another one‐carbon source such as triethyl orthoacetate or triethyl orthobenzoate. The nucleic

  合成了一些新的6-氨基-1,3-二甲基-5-（取代亚甲基）氨基尿嘧啶。它们中的大多数与原甲酸三乙酯作为单碳源环化，得到 1,3-二甲基-6-取代的蝶啶衍生物。某些尿嘧啶在使用另一种单碳源（如原乙酸三乙酯或原苯甲酸三乙酯）时产生黄嘌呤而不是预期的蝶啶衍生物。核酸结合试验表明，与仅对 DNA 具有亲和力的阿昔洛韦相反，一些新化合物显示出高亲和力、螯合和核酸片段化，无论是 DNA 还是 RNA。这些新型化合物的抗病毒活性表明，化合物 2e 和 2f 分别将 Vero 细胞培养物中小反刍兽疫病毒 (PPRV) 的细胞致病性降低了 60% 和 50%。
• Low glycemic response compositions
  申请人：The Procter & Gamble Co.

  公开号：US20020187219A1

  公开（公告）日：2002-12-12

  The present disclosure is related to compositions useful in the field of foods and beverages. In particular, the present invention relates to those compositions that reduce the postprandial rise in blood glucose (described as low Glycemic Index) that synergistically provide enhanced metabolism in the mammalian system and inhibit the storage of systemic fat. In particular, the present invention relates to compositions comprising: a) one or more flavanols; b) one or more bracers; and c) vitamin B; wherein the composition exhibits a Glycemic Index of about 55 or less. As disclosed, the unique combination of ingredients, which provide the defined, low Glycemic Index, work synergistically together to enhance perception of energy and/or improve physiological energy via metabolism enhancement over a long duration of time, without resulting in sudden peaks of glucose in the mammalian system. Thus, the present compositions effectively modulate glucose in the system, thereby providing energy to the system without resulting in the storage of systemic fat.

  本公开涉及在食品和饮料领域有用的组合物。特别是，本发明涉及那些能够减少餐后血糖上升（描述为低升糖指数）的组合物，这些组合物在哺乳动物系统中协同作用，提供增强的代谢作用并抑制系统性脂肪的储存。特别是，本发明涉及包括：a）一种或多种黄烷醇；b）一种或多种支链氨基酸；和c）维生素B的组合物；其中该组合物表现出约55或更低的升糖指数。如本文所述，这些独特的成分组合，以定义的低升糖指数为特征，协同作用，能够提高能量感知和/或通过代谢增强长时间改善生理能量，而不会导致哺乳动物系统中的血糖突然峰值。因此，本组合物有效地调节系统中的葡萄糖，从而为系统提供能量而不导致系统性脂肪的储存。
• Compositions, kits, and methods for promoting defined health benefits
  申请人：——

  公开号：US20030069202A1

  公开（公告）日：2003-04-10

  The present invention is directed to compositions comprising: (a) a first component selected from the group consisting of gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixtures thereof; and (b) a second component comprising: (i) a cation source selected from the group consisting of calcium, potassium, magnesium, and mixtures thereof; and (ii) an edible acid source. The present invention is further directed to food, beverage, pharmaceutical, over-the- counter, and dietary supplement products, which comprise the present compositions. The invention also relates to kits comprising the present compositions and information that use of the composition promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention additionally relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein.

  本发明涉及包括以下组分的组合物：(a)从明胶、软骨、氨基糖、糖胶质、甲基磺酰甲烷、甲基磺酰甲烷的前体、S-腺苷甲硫氨酸、其盐和其混合物中选择的第一组分; 和(b)包括：(i)从钙、钾、镁和其混合物中选择的阳离子源; 和(ii)可食用的酸源的第二组分。本发明还涉及包含本组合物的食品、饮料、制药、非处方药和膳食补充剂产品。本发明还涉及包含本组合物和使用该组合物促进当前定义的健康益处之一或多个的信息的套件。本发明还涉及治疗关节功能、骨功能、心脏功能或炎症的方法，包括向哺乳动物投与本文所定义的组合物。